Share Price and Basic Stock Data
Last Updated: January 14, 2026, 2:50 pm
| PEG Ratio | 1.71 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Blue Jet Healthcare Ltd operates in the pharmaceuticals sector, a field characterized by its critical role in healthcare and consistent demand. For the fiscal year ending March 2025, the company reported sales of ₹1,030 Cr, an increase from ₹721 Cr in the previous year, reflecting a robust growth trajectory. The trailing twelve months (TTM) sales stood at ₹1,179 Cr, suggesting strong operational momentum. Quarterly sales data reveals fluctuations, with the highest quarterly sales recorded in December 2024 at ₹318 Cr, while the lowest was in December 2023 at ₹167 Cr. This variability indicates a responsive market strategy, adjusting to consumer needs and market conditions. The overall sales growth aligns with the pharmaceutical industry’s average growth rate, which is typically around 10-15% annually, according to industry reports. The company’s ability to generate sustainable revenue growth positions it well in a competitive sector.
Profitability and Efficiency Metrics
Blue Jet Healthcare’s profitability metrics showcase a strong operational foundation. The operating profit margin (OPM) for the fiscal year ending March 2025 stood at 37%, up from 30% in March 2023, indicating improved cost management and efficiency. The net profit for the same period was reported at ₹305 Cr, representing a significant increase from ₹160 Cr in the previous fiscal year. The return on equity (ROE) was an impressive 30.2%, suggesting that the company effectively generates profits relative to shareholders’ equity. Additionally, the interest coverage ratio (ICR) was a robust 40.49x, underscoring Blue Jet’s ability to meet its interest obligations comfortably. However, the cash conversion cycle (CCC) increased to 262 days, indicating potential inefficiencies in working capital management that could impact liquidity. Overall, the profitability metrics reflect a strong business model, but the CCC raises questions about operational efficiency.
Balance Sheet Strength and Financial Ratios
Blue Jet Healthcare’s balance sheet demonstrates significant financial strength, with total assets reported at ₹1,527 Cr as of September 2025. The company’s reserves have increased to ₹1,221 Cr, providing a solid buffer for future investments and operational needs. Borrowings remained low at ₹21 Cr, indicating a conservative capital structure and minimal reliance on debt, which is favorable compared to industry norms. The debt-to-equity ratio was notably low, reflecting a strong equity position. Financial ratios such as the return on capital employed (ROCE) stood at 39.8%, significantly above average sector benchmarks, indicating efficient utilization of capital. The company’s ability to maintain high profitability while keeping debt levels low enhances its financial stability. However, the increasing cash conversion cycle could pose challenges in liquidity management, warranting close monitoring.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Blue Jet Healthcare Ltd indicates strong promoter confidence, with promoters holding 79.81% of shares as of September 2025. This high level of ownership underscores management’s commitment to the company’s growth and aligns their interests with those of minority shareholders. Foreign institutional investors (FIIs) and domestic institutional investors (DIIs) hold 1.83% and 3.63% of shares, respectively, reflecting cautious interest in the stock. The public shareholding has increased to 14.74%, indicating growing interest among retail investors. The number of shareholders has also risen significantly, reaching 80,117, suggesting enhanced market participation. The stability in promoter holding, combined with increasing public interest, points towards a generally positive investor sentiment, although the relatively low FII and DII participation may indicate a need for improved investor relations or visibility in the market.
Outlook, Risks, and Final Insight
Blue Jet Healthcare’s outlook remains optimistic, driven by strong revenue growth and profitability metrics. However, risks are present, particularly regarding the increasing cash conversion cycle, which could impact operational liquidity. Additionally, fluctuations in quarterly sales may indicate vulnerability to market dynamics. The company’s low debt levels provide a cushion against financial distress, yet reliance on effective working capital management is crucial. The pharmaceutical sector is subject to regulatory changes and competitive pressures, which could affect future performance. Strengths include high ROE and a solid reserve base, while risks involve operational inefficiencies and market volatility. Overall, Blue Jet Healthcare’s fundamentals position it well for sustained growth, provided it addresses its liquidity management and operational efficiency challenges effectively.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 130 Cr. | 103 | 208/84.3 | 28.7 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.21 Cr. | 1.68 | 4.29/1.68 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,065 Cr. | 373 | 479/192 | 84.2 | 24.3 | 0.18 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 33.4 Cr. | 45.0 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.6 Cr. | 40.0 | 41.0/17.0 | 139 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,199.61 Cr | 1,121.95 | 52.58 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 190 | 169 | 217 | 180 | 181 | 167 | 184 | 163 | 208 | 318 | 340 | 355 | 165 |
| Expenses | 132 | 117 | 147 | 121 | 119 | 112 | 131 | 119 | 139 | 194 | 200 | 234 | 111 |
| Operating Profit | 59 | 52 | 70 | 59 | 63 | 55 | 53 | 44 | 69 | 124 | 140 | 121 | 55 |
| OPM % | 31% | 31% | 32% | 33% | 35% | 33% | 29% | 27% | 33% | 39% | 41% | 34% | 33% |
| Other Income | 7 | 6 | 6 | 5 | 8 | -3 | 9 | 9 | 12 | 13 | 12 | 8 | 24 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 |
| Depreciation | 6 | 7 | 6 | 6 | 6 | 8 | 8 | 3 | 5 | 5 | 5 | 6 | 6 |
| Profit before tax | 59 | 51 | 70 | 58 | 64 | 44 | 54 | 49 | 77 | 132 | 147 | 123 | 69 |
| Tax % | 26% | 27% | 27% | 24% | 26% | 27% | 27% | 24% | 24% | 25% | 25% | 26% | 24% |
| Net Profit | 44 | 38 | 51 | 44 | 48 | 32 | 40 | 38 | 58 | 99 | 110 | 91 | 52 |
| EPS in Rs | 2.53 | 2.16 | 2.92 | 2.54 | 2.76 | 1.85 | 2.29 | 2.18 | 3.36 | 5.71 | 6.35 | 5.26 | 3.01 |
Last Updated: December 27, 2025, 6:06 pm
Below is a detailed analysis of the quarterly data for Blue Jet Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 165.00 Cr.. The value appears to be declining and may need further review. It has decreased from 355.00 Cr. (Jun 2025) to 165.00 Cr., marking a decrease of 190.00 Cr..
- For Expenses, as of Sep 2025, the value is 111.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 234.00 Cr. (Jun 2025) to 111.00 Cr., marking a decrease of 123.00 Cr..
- For Operating Profit, as of Sep 2025, the value is 55.00 Cr.. The value appears to be declining and may need further review. It has decreased from 121.00 Cr. (Jun 2025) to 55.00 Cr., marking a decrease of 66.00 Cr..
- For OPM %, as of Sep 2025, the value is 33.00%. The value appears to be declining and may need further review. It has decreased from 34.00% (Jun 2025) to 33.00%, marking a decrease of 1.00%.
- For Other Income, as of Sep 2025, the value is 24.00 Cr.. The value appears strong and on an upward trend. It has increased from 8.00 Cr. (Jun 2025) to 24.00 Cr., marking an increase of 16.00 Cr..
- For Interest, as of Sep 2025, the value is 5.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.00 Cr. (Jun 2025) to 5.00 Cr., marking an increase of 4.00 Cr..
- For Depreciation, as of Sep 2025, the value is 6.00 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 6.00 Cr..
- For Profit before tax, as of Sep 2025, the value is 69.00 Cr.. The value appears to be declining and may need further review. It has decreased from 123.00 Cr. (Jun 2025) to 69.00 Cr., marking a decrease of 54.00 Cr..
- For Tax %, as of Sep 2025, the value is 24.00%. The value appears to be improving (decreasing) as expected. It has decreased from 26.00% (Jun 2025) to 24.00%, marking a decrease of 2.00%.
- For Net Profit, as of Sep 2025, the value is 52.00 Cr.. The value appears to be declining and may need further review. It has decreased from 91.00 Cr. (Jun 2025) to 52.00 Cr., marking a decrease of 39.00 Cr..
- For EPS in Rs, as of Sep 2025, the value is 3.01. The value appears to be declining and may need further review. It has decreased from 5.26 (Jun 2025) to 3.01, marking a decrease of 2.25.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 4:02 am
| Metric | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 538 | 499 | 683 | 721 | 712 | 1,030 | 1,179 |
| Expenses | 325 | 292 | 434 | 502 | 481 | 652 | 739 |
| Operating Profit | 214 | 207 | 249 | 219 | 231 | 378 | 440 |
| OPM % | 40% | 41% | 36% | 30% | 32% | 37% | 37% |
| Other Income | 6 | 9 | 19 | 24 | 18 | 46 | 58 |
| Interest | 7 | 5 | 3 | 1 | 0 | 0 | 5 |
| Depreciation | 18 | 20 | 22 | 25 | 28 | 18 | 21 |
| Profit before tax | 194 | 190 | 243 | 217 | 220 | 406 | 471 |
| Tax % | 25% | 26% | 25% | 26% | 26% | 25% | |
| Net Profit | 145 | 142 | 182 | 160 | 164 | 305 | 352 |
| EPS in Rs | 24,118.33 | 1,428.77 | 10.47 | 9.23 | 9.44 | 17.59 | 20.33 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 11% | 7% |
YoY Net Profit Growth
| Year | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -2.07% | 28.17% | -12.09% | 2.50% | 85.98% |
| Change in YoY Net Profit Growth (%) | 0.00% | 30.24% | -40.26% | 14.59% | 83.48% |
Blue Jet Healthcare Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 5 years from 2020-2021 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 14% |
| 3 Years: | 15% |
| TTM: | 76% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 16% |
| 3 Years: | 19% |
| TTM: | 118% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 48% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 31% |
| 3 Years: | 27% |
| Last Year: | 31% |
Last Updated: September 5, 2025, 2:45 pm
Balance Sheet
Last Updated: December 4, 2025, 2:33 am
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.60 | 10 | 35 | 35 | 35 | 35 | 35 |
| Reserves | 198 | 330 | 487 | 647 | 811 | 1,098 | 1,221 |
| Borrowings | 74 | 52 | 19 | 5 | 3 | 21 | 21 |
| Other Liabilities | 92 | 142 | 173 | 176 | 211 | 263 | 251 |
| Total Liabilities | 364 | 534 | 713 | 862 | 1,059 | 1,418 | 1,527 |
| Fixed Assets | 107 | 139 | 156 | 151 | 172 | 300 | 303 |
| CWIP | 2 | 3 | 3 | 30 | 147 | 89 | 159 |
| Investments | 26 | 37 | 94 | 189 | 250 | 187 | 210 |
| Other Assets | 229 | 355 | 460 | 491 | 489 | 841 | 855 |
| Total Assets | 364 | 534 | 713 | 862 | 1,059 | 1,418 | 1,527 |
Below is a detailed analysis of the balance sheet data for Blue Jet Healthcare Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 35.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 35.00 Cr..
- For Reserves, as of Sep 2025, the value is 1,221.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,098.00 Cr. (Mar 2025) to 1,221.00 Cr., marking an increase of 123.00 Cr..
- For Borrowings, as of Sep 2025, the value is 21.00 Cr.. The value remains steady. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. There is no change compared to the previous period (Mar 2025) which recorded 21.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 251.00 Cr.. The value appears to be improving (decreasing). It has decreased from 263.00 Cr. (Mar 2025) to 251.00 Cr., marking a decrease of 12.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 1,527.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1,418.00 Cr. (Mar 2025) to 1,527.00 Cr., marking an increase of 109.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 303.00 Cr.. The value appears strong and on an upward trend. It has increased from 300.00 Cr. (Mar 2025) to 303.00 Cr., marking an increase of 3.00 Cr..
- For CWIP, as of Sep 2025, the value is 159.00 Cr.. The value appears strong and on an upward trend. It has increased from 89.00 Cr. (Mar 2025) to 159.00 Cr., marking an increase of 70.00 Cr..
- For Investments, as of Sep 2025, the value is 210.00 Cr.. The value appears strong and on an upward trend. It has increased from 187.00 Cr. (Mar 2025) to 210.00 Cr., marking an increase of 23.00 Cr..
- For Other Assets, as of Sep 2025, the value is 855.00 Cr.. The value appears strong and on an upward trend. It has increased from 841.00 Cr. (Mar 2025) to 855.00 Cr., marking an increase of 14.00 Cr..
- For Total Assets, as of Sep 2025, the value is 1,527.00 Cr.. The value appears strong and on an upward trend. It has increased from 1,418.00 Cr. (Mar 2025) to 1,527.00 Cr., marking an increase of 109.00 Cr..
Notably, the Reserves (1,221.00 Cr.) exceed the Borrowings (21.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Free Cash Flow | 140.00 | 155.00 | 230.00 | 214.00 | 228.00 | 357.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|
| Debtor Days | 80 | 105 | 121 | 121 | 91 | 124 |
| Inventory Days | 120 | 201 | 133 | 137 | 151 | 209 |
| Days Payable | 90 | 101 | 72 | 58 | 35 | 70 |
| Cash Conversion Cycle | 110 | 204 | 183 | 199 | 206 | 262 |
| Working Capital Days | 55 | 105 | 103 | 120 | 92 | 157 |
| ROCE % | 58% | 53% | 35% | 30% | 40% |
Mutual Fund Holdings
| Fund Name | No of Shares | AUM (%) | Amount Invested (Cr) | Previous Number of Shares | Previous Date | Percentage Change |
|---|---|---|---|---|---|---|
| ICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund | 1,572,468 | 1.41 | 90.96 | 1,121,784 | 2025-12-14 06:41:48 | 40.18% |
| UTI Small Cap Fund | 506,107 | 0.61 | 29.28 | N/A | N/A | N/A |
| PGIM India Flexi Cap Fund | 421,553 | 0.38 | 24.38 | N/A | N/A | N/A |
| JM Flexicap Fund | 419,500 | 0.4 | 24.27 | N/A | N/A | N/A |
| JM Midcap Fund | 139,800 | 0.55 | 8.09 | N/A | N/A | N/A |
| JM ELSS Tax Saver Fund | 53,400 | 1.35 | 3.09 | N/A | N/A | N/A |
| JM Aggressive Hybrid Fund | 47,900 | 0.34 | 2.77 | N/A | N/A | N/A |
| JM Large Cap Fund | 41,900 | 0.5 | 2.42 | N/A | N/A | N/A |
Key Financial Ratios
| Month | Mar 21 | Mar 20 |
|---|---|---|
| FaceValue | 100.00 | 100.00 |
| Basic EPS (Rs.) | 1396.27 | 1462.59 |
| Diluted EPS (Rs.) | 1396.27 | 1462.59 |
| Cash EPS (Rs.) | 1568.30 | 27166.33 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 3428.34 | 32238.33 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 3428.34 | 32238.33 |
| Revenue From Operations / Share (Rs.) | 5033.61 | 89699.16 |
| PBDIT / Share (Rs.) | 2168.43 | 36589.16 |
| PBIT / Share (Rs.) | 1970.05 | 33582.66 |
| PBT / Share (Rs.) | 1862.96 | 32354.50 |
| Net Profit / Share (Rs.) | 1369.92 | 24159.83 |
| NP After MI And SOA / Share (Rs.) | 1396.43 | 24141.33 |
| PBDIT Margin (%) | 43.07 | 40.79 |
| PBIT Margin (%) | 39.13 | 37.43 |
| PBT Margin (%) | 37.01 | 36.07 |
| Net Profit Margin (%) | 27.21 | 26.93 |
| NP After MI And SOA Margin (%) | 27.74 | 26.91 |
| Return on Networth / Equity (%) | 40.73 | 75.40 |
| Return on Capital Employeed (%) | 52.32 | 83.21 |
| Return On Assets (%) | 25.94 | 38.58 |
| Long Term Debt / Equity (X) | 0.08 | 0.19 |
| Total Debt / Equity (X) | 0.10 | 0.30 |
| Asset Turnover Ratio (%) | 1.10 | 0.00 |
| Current Ratio (X) | 2.43 | 1.89 |
| Quick Ratio (X) | 1.69 | 1.37 |
| Inventory Turnover Ratio (X) | 2.30 | 0.00 |
| Interest Coverage Ratio (X) | 40.49 | 29.79 |
| Interest Coverage Ratio (Post Tax) (X) | 27.58 | 20.67 |
After reviewing the key financial ratios for Blue Jet Healthcare Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 21, the value is 100.00. This value exceeds the healthy maximum of 10. There is no change compared to the previous period (Mar 20) which recorded 100.00.
- For Basic EPS (Rs.), as of Mar 21, the value is 1,396.27. This value is within the healthy range. It has decreased from 1,462.59 (Mar 20) to 1,396.27, marking a decrease of 66.32.
- For Diluted EPS (Rs.), as of Mar 21, the value is 1,396.27. This value is within the healthy range. It has decreased from 1,462.59 (Mar 20) to 1,396.27, marking a decrease of 66.32.
- For Cash EPS (Rs.), as of Mar 21, the value is 1,568.30. This value is within the healthy range. It has decreased from 27,166.33 (Mar 20) to 1,568.30, marking a decrease of 25,598.03.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 21, the value is 3,428.34. It has decreased from 32,238.33 (Mar 20) to 3,428.34, marking a decrease of 28,809.99.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 21, the value is 3,428.34. It has decreased from 32,238.33 (Mar 20) to 3,428.34, marking a decrease of 28,809.99.
- For Revenue From Operations / Share (Rs.), as of Mar 21, the value is 5,033.61. It has decreased from 89,699.16 (Mar 20) to 5,033.61, marking a decrease of 84,665.55.
- For PBDIT / Share (Rs.), as of Mar 21, the value is 2,168.43. This value is within the healthy range. It has decreased from 36,589.16 (Mar 20) to 2,168.43, marking a decrease of 34,420.73.
- For PBIT / Share (Rs.), as of Mar 21, the value is 1,970.05. This value is within the healthy range. It has decreased from 33,582.66 (Mar 20) to 1,970.05, marking a decrease of 31,612.61.
- For PBT / Share (Rs.), as of Mar 21, the value is 1,862.96. This value is within the healthy range. It has decreased from 32,354.50 (Mar 20) to 1,862.96, marking a decrease of 30,491.54.
- For Net Profit / Share (Rs.), as of Mar 21, the value is 1,369.92. This value is within the healthy range. It has decreased from 24,159.83 (Mar 20) to 1,369.92, marking a decrease of 22,789.91.
- For NP After MI And SOA / Share (Rs.), as of Mar 21, the value is 1,396.43. This value is within the healthy range. It has decreased from 24,141.33 (Mar 20) to 1,396.43, marking a decrease of 22,744.90.
- For PBDIT Margin (%), as of Mar 21, the value is 43.07. This value is within the healthy range. It has increased from 40.79 (Mar 20) to 43.07, marking an increase of 2.28.
- For PBIT Margin (%), as of Mar 21, the value is 39.13. This value exceeds the healthy maximum of 20. It has increased from 37.43 (Mar 20) to 39.13, marking an increase of 1.70.
- For PBT Margin (%), as of Mar 21, the value is 37.01. This value is within the healthy range. It has increased from 36.07 (Mar 20) to 37.01, marking an increase of 0.94.
- For Net Profit Margin (%), as of Mar 21, the value is 27.21. This value exceeds the healthy maximum of 10. It has increased from 26.93 (Mar 20) to 27.21, marking an increase of 0.28.
- For NP After MI And SOA Margin (%), as of Mar 21, the value is 27.74. This value exceeds the healthy maximum of 20. It has increased from 26.91 (Mar 20) to 27.74, marking an increase of 0.83.
- For Return on Networth / Equity (%), as of Mar 21, the value is 40.73. This value is within the healthy range. It has decreased from 75.40 (Mar 20) to 40.73, marking a decrease of 34.67.
- For Return on Capital Employeed (%), as of Mar 21, the value is 52.32. This value is within the healthy range. It has decreased from 83.21 (Mar 20) to 52.32, marking a decrease of 30.89.
- For Return On Assets (%), as of Mar 21, the value is 25.94. This value is within the healthy range. It has decreased from 38.58 (Mar 20) to 25.94, marking a decrease of 12.64.
- For Long Term Debt / Equity (X), as of Mar 21, the value is 0.08. This value is below the healthy minimum of 0.2. It has decreased from 0.19 (Mar 20) to 0.08, marking a decrease of 0.11.
- For Total Debt / Equity (X), as of Mar 21, the value is 0.10. This value is within the healthy range. It has decreased from 0.30 (Mar 20) to 0.10, marking a decrease of 0.20.
- For Asset Turnover Ratio (%), as of Mar 21, the value is 1.10. It has increased from 0.00 (Mar 20) to 1.10, marking an increase of 1.10.
- For Current Ratio (X), as of Mar 21, the value is 2.43. This value is within the healthy range. It has increased from 1.89 (Mar 20) to 2.43, marking an increase of 0.54.
- For Quick Ratio (X), as of Mar 21, the value is 1.69. This value is within the healthy range. It has increased from 1.37 (Mar 20) to 1.69, marking an increase of 0.32.
- For Inventory Turnover Ratio (X), as of Mar 21, the value is 2.30. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 20) to 2.30, marking an increase of 2.30.
- For Interest Coverage Ratio (X), as of Mar 21, the value is 40.49. This value is within the healthy range. It has increased from 29.79 (Mar 20) to 40.49, marking an increase of 10.70.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 21, the value is 27.58. This value is within the healthy range. It has increased from 20.67 (Mar 20) to 27.58, marking an increase of 6.91.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Blue Jet Healthcare Ltd:
- Net Profit Margin: 27.21%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 52.32% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 40.73% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 27.58
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.69
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 24.2 (Industry average Stock P/E: 52.58)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0.1
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 27.21%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | 701, 702, 7th Floor, Navi Mumbai Maharashtra 400705 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Akshay Bansarilal Arora | Executive Chairman |
| Mr. Shiven Akshay Arora | Managing Director |
| Mr. Naresh Suryakant Shah | Executive Director |
| Mr. Popat B Kedar | Executive Director |
| Ms. Divya Sameer Momaya | Independent Director |
| Mr. Girish Paman Vanvari | Independent Director |
| Ms. Preeti Gautam Mehta | Independent Director |
| Ms. Priyanka Yadav | Independent Director |
FAQ
What is the intrinsic value of Blue Jet Healthcare Ltd?
Blue Jet Healthcare Ltd's intrinsic value (as of 14 January 2026) is ₹424.32 which is 13.76% lower the current market price of ₹492.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹8,541 Cr. market cap, FY2025-2026 high/low of ₹1,028/490, reserves of ₹1,221 Cr, and liabilities of ₹1,527 Cr.
What is the Market Cap of Blue Jet Healthcare Ltd?
The Market Cap of Blue Jet Healthcare Ltd is 8,541 Cr..
What is the current Stock Price of Blue Jet Healthcare Ltd as on 14 January 2026?
The current stock price of Blue Jet Healthcare Ltd as on 14 January 2026 is ₹492.
What is the High / Low of Blue Jet Healthcare Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Blue Jet Healthcare Ltd stocks is ₹1,028/490.
What is the Stock P/E of Blue Jet Healthcare Ltd?
The Stock P/E of Blue Jet Healthcare Ltd is 24.2.
What is the Book Value of Blue Jet Healthcare Ltd?
The Book Value of Blue Jet Healthcare Ltd is 72.4.
What is the Dividend Yield of Blue Jet Healthcare Ltd?
The Dividend Yield of Blue Jet Healthcare Ltd is 0.24 %.
What is the ROCE of Blue Jet Healthcare Ltd?
The ROCE of Blue Jet Healthcare Ltd is 39.8 %.
What is the ROE of Blue Jet Healthcare Ltd?
The ROE of Blue Jet Healthcare Ltd is 30.2 %.
What is the Face Value of Blue Jet Healthcare Ltd?
The Face Value of Blue Jet Healthcare Ltd is 2.00.